Azathioprine and 6-Mercaptopurine use in the Swiss IBD cohort : adverse effects, causes of discontinuation and risk of "flares" according to 6-TG levels
Fiche du document
2015
- handle: 10670/1.la0f0e
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/isbn/1873-9946
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_0CE49558DEF85
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Therapy Instruction and study--Methods Description Description, geography Treatments for diseases Medical treatment Therapy Treatment of diseases Survival skills Survival after airplane accidents, shipwrecks, etc Judgement Pattern Model Red blood corpuscles Red blood cells Red cells Ileitis, Regional Colitis, Granulomatous Regional enteritis Crohn disease Regional ileitis Enteritis, Regional Ileocolitis Granulomatous colitis Terminal enteritis Granulomatous enteritis Instruction and study--MethodsCiter ce document
D. Lavrek et al., « Azathioprine and 6-Mercaptopurine use in the Swiss IBD cohort : adverse effects, causes of discontinuation and risk of "flares" according to 6-TG levels », Serveur académique Lausannois, ID : 10670/1.la0f0e
Métriques
Partage / Export
Résumé
Background: To characterize and analyze in the Swiss IBD Cohort: a) reported Azathioprine (AZA) and 6-Mercaptopurine (6-MP) adverse effects (AE), b) causes of discontinuation and c) response to therapy according to gastroenterologists' clinical judgment, d) whether level of 6-TGN < 235pmol/8 x108 red blood cells (RBC) is associated with a higher risk of "flare" occurrence. Methods: Retrospective statistical description, Cox model and Kaplan-Meier survival estimation. Results: 1499 patients with Crohn's Disease (CD) and 1066 with Ulcerative colitis (UC).